NEW YORK – Whole-genome sequencing may be a practical method for finding markers to guide treatment in metastatic cancer patients, new research suggests.
At the European Society for Medical Oncology's Virtual Congress on Saturday, pathologist Kim Monkhorst from the Netherlands Cancer Institute shared interim results for the first 800 of the 1,200 patients who will be profiled through the "Whole-genome sequencing implementation and standard of care diagnostics for every cancer patient," or WIDE, study.